Study summary
Cenobamate made about half of patients seizure-free at the highest dose
52.4%seizure-free during maintenance with 400 mg, vs 2.6% with placebo
What was tested
Cenobamate at three doses or placebo added to existing medicines in adults with uncontrolled focal seizures, in China, Japan and South Korea.
What they found
- Seizure-free rates during maintenance were 52.4% with 400 mg, 30.1% with 200 mg and 2.6% with placebo.
- Dizziness and sleepiness were the most common side effects.
What it means
Confirms cenobamate as one of the most effective add-on medicines for focal epilepsy.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.